Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Deferred Taxes (2016 - 2021)

ImmunityBio (IBRX) has disclosed Deferred Taxes for 6 consecutive years, with -$8000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Deferred Taxes rose 96.14% to -$8000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$8000.0, a 99.73% increase, with the full-year FY2022 number at -$4000.0, up 50.0% from a year prior.
  • Deferred Taxes was -$8000.0 for Q4 2021 at ImmunityBio, up from -$207000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $38000.0 in Q2 2020 to a low of -$1.7 million in Q3 2020.
  • A 5-year average of -$282071.4 and a median of -$124000.0 in 2017 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: crashed 2487.5% in 2020, then skyrocketed 96.14% in 2021.
  • ImmunityBio's Deferred Taxes stood at -$182000.0 in 2017, then skyrocketed by 32.97% to -$122000.0 in 2018, then skyrocketed by 93.44% to -$8000.0 in 2019, then plummeted by 2487.5% to -$207000.0 in 2020, then surged by 96.14% to -$8000.0 in 2021.
  • Per Business Quant, the three most recent readings for IBRX's Deferred Taxes are -$8000.0 (Q4 2021), -$207000.0 (Q4 2020), and -$1.7 million (Q3 2020).